{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:14:22Z","timestamp":1794978862606,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Enabling greater flexibility for lifecycle management of analytical procedures is one of the primary features of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q12 Lifecycle Management guideline. Rather than rely on a comparatively slower and burdensome post-approval change supplement process, ICH Q12 created a new pathway to facilitate changes to chemistry, manufacturing, and controls. The new framework utilized key concepts such as established conditions (ECs), post-approval change management protocols, and the product lifecycle management document to allow modifications to analytical procedures based upon pre-approved conditions. Shortly after the publication of ICH Q12, the ICH Q14 Analytical Procedure Development guideline provided further guidance on how knowledge gained during analytical procedure development could be incorporated with the ICH Q12 framework to support scientifically sound and risk-based post-approval changes. However, to date, the full potential of ICH Q12 and Q14 remains unrealized, likely due to uncertainty over how analytical procedure development data can be effectively utilized to gain regulatory flexibility for post-approval changes. In this case study, an example of determining, proposing, and justifying analytical procedure ECs, reporting categories, and identification of elements not considered ECs is presented. In addition, how such information could be presented in a regulatory submission is described. Importantly, this case study serves as an example of the application of ICH Q12 and Q14 principles for analytical procedures, but it is not intended to serve as official guidance nor to define the full scope of information required in a regulatory submission.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01037-6","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:50:42Z","timestamp":1741971042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Enhanced Analytical Procedure Development in Facilitating Post-Approval Changes Via Established Conditions"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-5737","authenticated-orcid":false,"given":"Douglas","family":"Kirkpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirzari","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Gopalaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kolhatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hudson-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Keire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"100239","DOI":"10.1016\/j.ijpx.2024.100239","volume":"7","author":"R Tran","year":"2024","unstructured":"Tran R, Fraser G, Fisher AC, Lee SL, Boam A, Tsinontides S, et al. A network of regulatory innovations to improve FDA quality assessments of human drug applications. Int J Pharm X. 2024;7:100239. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100239.","journal-title":"Int J Pharm X"},{"issue":"2","key":"1037_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1208\/s12248-016-9874-5","volume":"18","author":"LX Yu","year":"2016","unstructured":"Yu LX, Akseli I, Allen B, Amidon G, Bizjak TG, Boam A, et al. Advancing product quality: a summary of the second FDA\/PQRI conference. AAPS J. 2016;18(2):528\u201343. https:\/\/doi.org\/10.1208\/s12248-016-9874-5.","journal-title":"AAPS J"},{"key":"1037_CR3","unstructured":"Ramanadham M. ICH Q12: what industry needs to know. CDER Small Business and Industry Assistance Pharmaceutical Quality Symposium 2023. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/pharmaceutical-quality-symposium-2023-quality-supply-chainadvanced-manufacturing-10312023."},{"key":"1037_CR4","unstructured":"Technical and regulatory considerations for pharmaceutical product lifecycle managment Q12. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2019."},{"key":"1037_CR5","unstructured":"Established conditions pilot program. In: Health and human services food and drug administration. 2019. p. 4478\u20139."},{"key":"1037_CR6","unstructured":"Analytical procedure development Q14. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2023."},{"key":"1037_CR7","unstructured":"Patel H. ICH Q12 experiences. AAPS summer scientific forum. Minneapolis, MN: American Association of Pharmaceutical Scientists; 2023."},{"key":"1037_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.07.022","author":"J Zhang","year":"2024","unstructured":"Zhang J, Raghavachari R, Kirkpatrick DC, Keire DA, Xu X, Faustino PJ. Analytical procedure development and proposed established conditions: a case study of a mass spectrometry based NDSRI analytical procedure. J Pharm Sci. 2024. https:\/\/doi.org\/10.1016\/j.xphs.2024.07.022.","journal-title":"J Pharm Sci"},{"key":"1037_CR9","unstructured":"Downey C. Reflections on the FDA established conditions pilot. CASSS CMC Strategy Forum North America: California Separation Science Society; 2021."},{"issue":"2","key":"1037_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/acs.analchem.1c03854","volume":"94","author":"P Borman","year":"2022","unstructured":"Borman P, Campa C, Delpierre G, Hook E, Jackson P, Kelley W, et al. Selection of analytical technology and development of analytical procedures using the analytical target profile. Anal Chem. 2022;94(2):559\u201370. https:\/\/doi.org\/10.1021\/acs.analchem.1c03854.","journal-title":"Anal Chem"},{"key":"1037_CR11","unstructured":"Quality Risk Management Q9(R1). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2023."},{"key":"1037_CR12","doi-asserted-by":"publisher","unstructured":"Ferreira SLC, Caires AO, Borges TdS, Lima AMDS, Silva LOB, dos Santos WNL. Robustness evaluation in analytical methods optimized using experimental designs. Microchem J. 2017;131:163\u20139. https:\/\/doi.org\/10.1016\/j.microc.2016.12.004.","DOI":"10.1016\/j.microc.2016.12.004"},{"issue":"3","key":"1037_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jps.22325","volume":"100","author":"FG Vogt","year":"2011","unstructured":"Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Sci. 2011;100(3):797\u2013812. https:\/\/doi.org\/10.1002\/jps.22325.","journal-title":"J Pharm Sci"},{"key":"1037_CR14","doi-asserted-by":"publisher","unstructured":"N. Politis S, Colombo P, Colombo G, M. Rekkas D. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889\u2013901. https:\/\/doi.org\/10.1080\/03639045.2017.1291672","DOI":"10.1080\/03639045.2017.1291672"},{"issue":"2","key":"1037_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.aca.2007.07.011","volume":"597","author":"SLC Ferreira","year":"2007","unstructured":"Ferreira SLC, Bruns RE, Ferreira HS, Matos GD, David JM, Brand\u00e3o GC, et al. Box-Behnken design: An alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597(2):179\u201386.","journal-title":"Anal Chim Acta"},{"key":"1037_CR16","unstructured":"Guidance for Industry: Q8(R2) Pharmaceutical Development. In: Health and Human Services Food and Drug Administration. 2009."},{"issue":"5","key":"1037_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jpba.2004.06.018","volume":"37","author":"J Ermer","year":"2005","unstructured":"Ermer J, Ploss H-J. Validation in pharmaceutical analysis: Part II: central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data. J Pharm Biomed Anal. 2005;37(5):859\u201370. https:\/\/doi.org\/10.1016\/j.jpba.2004.06.018.","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"1037_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/0731-7085(90)80091-3","volume":"8","author":"JC Wahlich","year":"1990","unstructured":"Wahlich JC, Carr GP. Chromatographic system suitability tests \u2014 what should we be using? J Pharm Biomed Anal. 1990;8(8):619\u201323. https:\/\/doi.org\/10.1016\/0731-7085(90)80091-3.","journal-title":"J Pharm Biomed Anal"},{"key":"1037_CR19","unstructured":"Validation of Analytical Procedures Q2(R2). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2023."},{"key":"1037_CR20","unstructured":"ICH Q12: Implementation Considerations for FDA-Regulated Products. In: Health and Human Services Food and Drug Administration. 2021."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01037-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:28:51Z","timestamp":1742858931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01037-6","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This publication reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies. All authors have no personal or financial conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"61"}}